secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001935979-26-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q1 net loss $130.5M; pivotal epilepsy & obesity data due 2H 2026
-------------------------------------------------------------------------

- Net loss $130.5M ($0.88/sh) vs $221.7M ($2.17/sh) in Q1 2025; non-GAAP adjusted loss $102.2M ($0.69/sh).
- Cash, equivalents & securities totaled $351.8M at March 31, 2026.
- R&D spend fell to $103.8M from $187.6M, driven by program reprioritization and lower share-based compensation.
- Pivotal epilepsy (opakalim) topline readout and Phase 2 obesity (taldefgrobep) data expected in 2H 2026.
- Pivotal trials for BHV-1400 (IgAN) and BHV-1300 (Graves' disease) expected to initiate mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/0001935979-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/bhvn-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001935979-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer